**Star News, Xinzhi Biotech is about to release its 2023 annual report in the near future, and according to the performance express report released on February 28, the attributable net profit is 058.7 billion yuan, a year-on-year increase of 4651%。
Explanation of the operating performance and financial condition in the announcement of the performance report:
During the reporting period, the company's operating income is expected to be 190,895,91528 yuan, an increase of 035%；Net profit attributable to shareholders of the listed company is expected to be 58,720,66950 yuan, an expected increase of 46 over the same period last year51%；Net profit attributable to shareholders of the listed company after deducting non-operating gains and losses is expected to be 42,610,50714 yuan, an expected increase of 12 over the same period last year28%；Basic earnings per share are expected to increase by 1818%。
At the end of the reporting period, the company's total assets are expected to be 609,715,58216 yuan, a decrease of 4 compared with the projection at the beginning of the reporting period22%；Owner's equity attributable to shareholders of the listed company is expected to be 538,032,05246 yuan, a decrease of 300%；Total share capital 91,515,94100 yuan, the same as the beginning of the period; Net assets per share attributable to shareholders of the listed company is 588 yuan, a decrease of 2 from the beginning of the reporting period97%。(2) The main reasons for the change in performance.
The company's net profit attributable to shareholders of listed companies in 2023 is expected to be 58,720,66950 yuan, an expected increase of 46 over the same period last year51%；Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 42,610,50714 yuan, an expected increase of 12 over the same period last year28%。
The main reasons are as follows:
1) The company's product category changes in sales revenue, the proportion of biological sample processing instruments in total sales revenue increased, and the comprehensive gross profit margin increased slightly year-on-year.
2) During the reporting period, the company received a listing reward of 12 million yuan.
At the end of the reporting period, the company's total assets and owner's equity attributable to shareholders of listed companies decreased year-on-year, mainly due to the company's cash dividend payment of 5,490960,000, as well as the company's repurchase of shares to pay cash 2,773600,000. 3. Risk Warning.
This performance report is the preliminary accounting data of the company's financial department, which has not been audited by an accounting firm and does not constitute the company's performance commitment to investors, and the specific financial data will be disclosed in detail in the company's 2023 annual report. Investors are advised to make prudent decisions and pay attention to investment risks.
Fourth, the directory of documents for reference.
The balance sheet and income statement signed and sealed by the company's legal representative, the person in charge of accounting work and the person in charge of the accounting institution.
Board of Directors of Ningbo Xinzhi Biotechnology Co., Ltd. February 28, 2024.
The main business of Xinzhi Biotechnology (430685) is the research and development, production and sales of life science instruments.
There are no agency ratings on the stock in the last 90 days.
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.